Thus, as the Acat2 level in liver is decreased during HFD-induced obesity, our results suggest that liver-targeted adenoviral Acat2 overexpression represents a potential therapeutic strategy for obesity and its associated hypercholesterolaemia. Here, ACAT2 is linked to obesity disorder.